Health
Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM
Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study (NCT06694701), evaluating Gamifant® (emapalumab) in patients with interferon-gamma (IFNγ)-driven sepsis (IDS), were presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) by Professor Evangelos J. Giamarellos-Bourboulis, President of the Hellenic Institute for the Study of Sepsis. The EMBRACE study was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) as par
About this update from Swedish Orphan Biovitrum Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Primary endpoint: improvement in organ function observed in 60% of patients receiving high-dose emapalumab vs 40% with standard of care plus placebo","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"28-day mortality: 40% in the high-dose emapalumab group vs 52% in the placebo group","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Biomarker response: high-dose emapalumab associated with faster reduction of pro-inflammatory biomarkers linked to interferon-gamma signalling","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Emapalumab was generally well tolerated","length":39,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":427,"olType":false},{"type":"text","content":"STOCKHOLM, March 18, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study (NCT06694701), evaluating Gamifant® (emapalumab) in patients with interferon-gamma (IFNγ)-driven sepsis (IDS), were presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) by Professor Evangelos J. Giamarellos-Bourboulis, President of the Hellenic Institute for the Study of Sepsis. The EMBRACE study was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) as part of a research collaboration with Sobi.","length":607,"tagName":"p"},{"type":"text","content":""These findings support the concept that sepsis is not a single disease but a syndrome with different biological drivers," said Prof. Evangelos J. Giamarellos-Bourboulis, principal investigator of the EMBRACE study. "The EMBRACE study explores a precision medicine approach in which patients with interferon-gamma-driven immune dysregulation may benefit from targeted immunotherapy."","length":403,"tagName":"p"},{"type":"text","content":"Sepsis is a life-threatening condition caused by a dysregulated immune response to infection that can lead to organ failure and death. The EMBRACE Phase 2a study evaluated emapalumab in patients with IDS identified through biomarker profiling.","length":243,"tagName":"p"},{"type":"text","content":""Sepsis represents a leading cause of mortality worldwide and treatment options remain limited[i]. The interferon-gamma driven sepsis endotype shows an elevated morta...